C18 Ceramide-d3 (d18:1/18:0-d3) – 1 mg

Brand:
Cayman
CAS:
2011762-82-4
Storage:
-20
UN-No:
Non-Hazardous - /

C18 Ceramide-d3 (d18:1/18:0) is intended for use as an internal standard for the quantification of C18 Ceramide (d18:1/18:0) (Item No. 19556) by GC- or LC-MS. C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.{40029} Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.{13918} It is selectively downregulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.{40030} [Matreya, LLC. Catalog No. 2201]  

 

Available on backorder

SKU: 24396 - 1 mg Category:

Description

An internal standard for the quantification of C18 ceramide by GC- or LC-MS


Formal name: N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl-d3]-octadecanamide

Synonyms:  C18 Ceramide-d3|Cer(d18:1/18:0)-d3|Ceramide-d3 (d18:1/18:0-d3)

Molecular weight: 569

CAS: 2011762-82-4

Purity: ≥99% deuterated forms (d1-d3); ≤1% d0

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Lipid Biochemistry|Sphingolipids